Skip to main content

SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

Written by Customer Service on . Posted in Public Companies.

BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company’s Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022.

Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 billion. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, leading U.S. BioOncology for a period of unprecedented growth to over $12 billion while helping to steer the Roche Genentech R&D portfolio. Before Genentech, he held executive and senior roles of increasing responsibility including President of UCB BioPharmaceuticals, Senior Vice President of Sanofi-Aventis, and diverse foundational roles at Schering-Plough.

“We thank Mr. Lillis for serving as Chair for nearly 3 years and are grateful for his continued service as a board member. We are very pleased to appoint Mr. Cox as Executive Chair of SomaLogic’s Board of Directors,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “His input and guidance have been instrumental to our strategic and commercial progress through our 2021 Nasdaq listing and evolution as a public company. We look forward to leveraging his extensive leadership experience as we execute the next phase of SomaLogic’s growth.”

“I’m convinced that proteomics will become increasingly critical to the development of novel therapeutics and improving patient care. Somalogic is well positioned to lead the way,” said Cox. “I am inspired by this company’s future prospects and look forward to continuing my work with such a dedicated team as Executive Chair of the Board.”

About SomaLogic 
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.  

Media Contact  
Emilia Costales  
720-798-5054  
ecostales@somalogic.com   

Investor Contacts 
Lauren Glaser 
lglaser@somalogic.com 

Marissa Bych 
Gilmartin Group LLC 
Marissa@gilmartinir.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.